Novartis data show Cosentyx delivers high and long-lasting skin clearance over 4 years
Novartis announced data showing Cosentyx® (secukinumab) delivers high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis out to 4 years of treatment. Cosentyx continues to have a favorable safety profile consistent with that in previous Phase III studies.
October 01, 2016